Your browser is no longer supported. Please, upgrade your browser.
AGN Allergan plc daily Stock Chart
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-11.66 Insider Own0.20% Shs Outstand336.06M Perf Week-8.39%
Market Cap63.27B Forward P/E11.07 EPS next Y17.01 Insider Trans-0.27% Shs Float333.57M Perf Month-7.10%
Income-3981.80M PEG- EPS next Q4.06 Inst Own86.10% Short Float2.03% Perf Quarter-25.73%
Sales15.07B P/S4.20 EPS this Y63.30% Inst Trans0.07% Short Ratio2.45 Perf Half Y-20.55%
Book/sh209.70 P/B0.90 EPS next Y4.99% ROA8.90% Target Price250.72 Perf Year-19.22%
Cash/sh17.34 P/C10.86 EPS next 5Y11.27% ROE15.70% 52W Range182.80 - 256.80 Perf YTD-10.35%
Dividend2.80 P/FCF248.42 EPS past 5Y-28.70% ROI0.10% 52W High-26.68% Beta1.15
Dividend %1.49% Quick Ratio1.10 Sales past 5Y26.00% Gross Margin87.10% 52W Low3.00% ATR6.31
Employees16700 Current Ratio1.20 Sales Q/Q8.80% Oper. Margin-20.80% RSI (14)29.85 Volatility4.86% 2.88%
OptionableYes Debt/Eq0.43 EPS Q/Q-88.00% Profit Margin77.30% Rel Volume1.71 Prev Close189.27
ShortableYes LT Debt/Eq0.38 EarningsNov 01 BMO Payout5.00% Avg Volume2.77M Price188.28
Recom2.20 SMA20-7.87% SMA50-13.06% SMA200-18.68% Volume4,753,438 Change-0.52%
Oct-19-17Reiterated RBC Capital Mkts Outperform $277 → $250
Oct-17-17Reiterated UBS Buy $275 → $255
Oct-02-17Reiterated Barclays Equal Weight
Sep-25-17Reiterated RBC Capital Mkts Outperform $285 → $277
Sep-20-17Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-16-17Initiated Cantor Fitzgerald Neutral $231
Jun-09-17Reiterated Mizuho Buy $275 → $267
May-10-17Reiterated RBC Capital Mkts Outperform $279 → $284
May-10-17Downgrade Goldman Buy → Neutral
Feb-09-17Reiterated Mizuho Buy $273 → $275
Dec-09-16Reiterated Credit Suisse Outperform $301 → $274
Nov-17-16Reiterated Mizuho Buy $293 → $273
Nov-03-16Reiterated RBC Capital Mkts Outperform $300 → $279
Nov-01-16Reiterated Mizuho Buy $299 → $293
Oct-31-16Resumed Barclays Equal Weight $250
Oct-11-16Reiterated Mizuho Buy $305 → $299
Aug-19-16Upgrade Mizuho Neutral → Buy $248 → $318
Aug-09-16Reiterated RBC Capital Mkts Outperform $307 → $300
Aug-09-16Reiterated Deutsche Bank Buy $282 → $278
Aug-05-16Reiterated Mizuho Neutral $232 → $246
Oct-20-17 04:36PM  Allergan Stock: Performance in 3Q17 Market Realist
02:19PM  Allergan: A Splitting Headache?
01:24PM  US cash equities are the best risk-adjusted rate return in town: NYSE trader Yahoo Finance Video
08:47AM  Pharma Stock Roundup: Beat & Raise Quarter from J&J, Allergan Hit by Restasis Ruling Zacks
Oct-19-17 11:29PM  Imprimis Pharma to take on Allergan's Restasis with cheaper product Reuters
11:24AM  Allergan's Hard Fall Is Not Enough of a Reason to Buy
11:03AM  Allergan: All In or Fall Out?
10:04AM  Company News For Oct 19, 2017 Zacks
09:36AM  Conatus Entrusts Keith W. Marshall With Key Management Roles Zacks
Oct-18-17 06:45PM  Allergan Issues Investor FAQ on Federal District Court RESTASIS® Patent Decision PR Newswire -5.37%
05:55PM  The Biggest Loser: Allergan's Patent Troubles
04:30PM  Why SUPERVALU, Synchronoss Technologies, and Allergan Slumped Today Motley Fool
03:23PM  Mohawk Tribe sues Microsoft, Amazon for patent infringeme... CNBC Videos
02:33PM  Allergan Shares Are Ready for a 30% Bounce Within Days
02:33PM  4 health stocks and a gamer in the Blitz CNBC Videos
02:09PM  Native American tribe holding patents sues Amazon and Microsoft Reuters
11:26AM  Mohawk tribe sues Microsoft, Amazon for patent infringement CNBC
10:43AM  Allergan ruling casts doubt on tribal patent strategy Reuters
10:10AM  Is a Breakup Allergan's Best Bet?
Oct-17-17 07:01PM  Cramer: Getting Out the Bad News Gives a Post-Earnings Boost
06:17PM  Allergan ruling casts doubt on tribal patent strategy Reuters
05:59PM  Aerie (AERI) Up on FDA Review Committee Result for Rhopressa Zacks
05:44PM  Allergan (AGN) Loses Restasis Patent Lawsuit, Shares Fall Zacks
04:29PM  How Allergan's 'Public Relations Backlash' Deepened This Week Investor's Business Daily
03:59PM  And For Allergen's Next Trick..Filling a $1.5 Billion Hole?
12:39PM  Here's How Drug Companies Game the Patent System Bloomberg
10:07AM  Allergan Is the Cheapest Big-Cap Drug Stock in the Universe: Jim Cramer
10:00AM  3 Dividend Healthcare Stocks Motley Fool
08:40AM  Today's Research Reports on Stocks to Watch: Allergan and Gilead Sciences ACCESSWIRE
07:10AM  Allergan patent suit loss sends stock down 4% MarketWatch
Oct-16-17 07:59PM  [$$] Allergan Loses Patent Fight in Federal Court The Wall Street Journal
04:42PM  Allergan Tanks After Judge Invalidates Restasis Patents Investor's Business Daily
04:11PM  [$$] Allergan Loses Patent Fight in Federal Court The Wall Street Journal
03:45PM  Allergan will repeal Restasis patent decision CNBC Videos
03:35PM  Allergan Loses a Patent BattleHas It Lost the War?
02:33PM  Allergan patent suit loss sends stock down 5% MarketWatch
01:45PM  U.S. judge in Texas invalidates Allergan patents on Restasis Reuters
01:45PM  U.S. District Court for the Eastern District of Texas Issues Adverse Trial Decision Concerning RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patents PR Newswire
01:42PM  Allergan stock drops 5% after judge decides against company on key dry eye product MarketWatch
01:21PM  Allergan's Restasis patents invalidated by federal judge CNBC Videos
01:18PM  U.S. judge in Texas invalidates Allergan patents on Restasis Reuters
08:01AM  Allergan to Present New Data at the World Congress of Gastroenterology at ACG 2017 PR Newswire
01:00AM  Allergan Update; Fixed Income: Doug Kass' Views
12:17AM  [$$] Mylan Calls Allergans Patent Sale to Indian Tribe a Sham The Wall Street Journal
Oct-14-17 11:58AM  [$$] Mylan Calls Allergan's Patent Sale to Tribe a 'Sham' The Wall Street Journal
Oct-13-17 10:38AM  Trump to scrap a crucial part of Obamacare Yahoo Finance Video
08:06AM  Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback Zacks
06:05AM  3 Healthcare Value Stocks Motley Fool
Oct-12-17 06:45PM  Non-Alcoholic Steatohepatitis 2017 Progress Update Zacks
05:41PM  Allergan settles with one of four companies contesting Restasis patent Reuters
04:15PM  Allergan Announces Settlement on RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patent Litigation with InnoPharma, Inc. PR Newswire
10:30AM  Ardelyx IBS-C Candidate Succeeds in Pivotal Study, Stock Up Zacks
Oct-11-17 03:34PM  Allergan's Uterine Fibroids Candidate's NDA Accepted by FDA Zacks
09:45AM  Examining Consolidated Results on Allergan, Starbucks, Equifax, Walgreens, Texas Instruments, and Kraft Heinz Fundamental Analysis and Changes in Performance Indicators GlobeNewswire
08:01AM  Allergan to Present Data From More Than 20 Abstracts at the 2017 Fall Clinical Dermatology Conference PR Newswire
Oct-10-17 06:41PM  Health insurers, hospitals and generic-drug makers ask Congress to examine Allergan patent deal CNBC
05:22PM  Favorite stock picks from one of Wall Street's top biotech analysts CNBC
03:18PM  Allergan trading at a zero pipeline valuation: Evercore's... CNBC Videos
01:00PM  [$$] CVC Picks Former Allergan Executive to Run Women's Drug Portfolio The Wall Street Journal
08:01AM  Allergan Announces that the FDA Accepts New Drug Application for Ulipristal Acetate for Uterine Fibroids PR Newswire
03:19AM  'That should be illegal': Lawmakers are taking aim at pharma giant Allergan over an unusual deal with a Native American tribe Business Insider
Oct-09-17 03:56PM  Health Care Sector Back In Focus In Congress Ahead Of Q3 Earnings Result Benzinga
02:49PM  'That should be illegal': Lawmakers are taking aim at pharma giant Allergan over an unusual deal with a Native American tribe Business Insider
10:32AM  Valeant's Biggest Drug Gets a Shot at More Sales
08:30AM  Allergan to Present New Dry Eye Data at the American Academy of Optometry Meeting in Chicago PR Newswire
08:26AM  This billion-dollar dry eye drug is behind Allergans controversial patent deal MarketWatch
08:02AM  Rep. Peter Welch on Allergans bold, brazen, bizarre patent deal with an American Indian tribe MarketWatch
12:34AM  [$$] Reverse Patent Trolls Are Harming Drug Innovationand Patients The Wall Street Journal
Oct-08-17 07:12AM  [$$] Waxman hits out at Allergan patent deal with Mohawk tribe Financial Times
Oct-07-17 10:17AM  This billion-dollar dry eye drug is behind Allergans controversial patent deal MarketWatch
10:13AM  Rep. Peter Welch on Allergans bold, brazen, bizarre patent deal with an American Indian tribe MarketWatch
Oct-06-17 05:45PM  Judge asks if Allergan's patent deal with Mohawk tribe is a 'sham' CNBC
01:20PM  Bernstein analyst breaks down his best biotech picks CNBC Videos
11:00AM  Is Allergan plc a Bargain After a $7.6 Billion Dip in September? Motley Fool
09:07AM  Pharma Stock Roundup: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allergan Deal Zacks
Oct-05-17 10:54PM  'Nobody's talking about' 2 medical conditions that affect 8 million women in America but that could be about to change Business Insider
05:22PM  Senator McCaskill drafts bill in response to Allergan patent maneuver Reuters
12:05PM  Allergan Presents Data From Seventeen Abstracts At The 2017 American Society For Dermatologic Surgery Meeting In Chicago PR Newswire
11:45AM  3 Biotechs to Buy Ahead of Q3 Earnings
07:37AM  Changes in Eli Lillys Valuation Market Realist
06:03AM  3 Big Pharma Stocks Set to Succeed Motley Fool
Oct-04-17 11:40AM  Teva Shares Plummet After Mylan's Copaxone Generic Gets FDA Approval Zacks
09:45AM  6 Pharma Stocks to Buy Now
09:15AM  Allergan's Botox Gets FDA Nod for Forehead Line Treatment Zacks
08:01AM  Allergan To Present New Data From Its Anti-Infectives Portfolio At IDWeek 2017 In San Diego PR Newswire
Oct-03-17 04:43PM  U.S. House committee launches probe of Allergan patent deal Reuters
04:27PM  Drugmaker Under Fire For Using Mohawk Tribe To Shield Patent Investor's Business Daily
03:45PM  Allergan's unusual patent agreement CNBC Videos
01:23PM  Allergan Patent Deal May Hurt Competition, Lawmakers Say Bloomberg
12:53PM  Allergan CEO says patent review flawed in response to senators Reuters
10:19AM  [$$] Big Questions for Big Pharma
09:50AM  Allergan's sNDA for Anti-Infective Avycaz Accepted by FDA Zacks
09:45AM  Allergan responds to mounting criticism of Mohawk patent deal CNBC
07:37AM  Allergan's Botox gets FDA OK to treat forehead lines MarketWatch
07:31AM  FDA Approves BOTOX® Cosmetic (OnabotulinumtoxinA) for the Temporary Improvement in the Appearance of Moderate to Severe Forehead Lines Associated with Frontalis Muscle Activity In Adults PR Newswire
01:04AM  Shire Alleges Allergan Blocked Drug From Medicare Contracts The Wall Street Journal
Oct-02-17 08:28PM  Markets Move Higher; Inversion Rules Put Pfizer-Allergan Back In Focus -- ICYMI
06:31PM  More scrutiny for Allergan over Native American tribe deal CNBC
05:18PM  Senator questions Allergan deal CNBC Videos
04:40PM  [$$] Allergan leads drugmakers higher on repatriation hopes Financial Times
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SAUNDERS BRENT LChairman, President and CEOJun 16Buy235.964410,327131,178Sep 18 08:49 PM
Basgoz NesliDirectorMay 18Option Exercise84.441,889159,5077,919May 22 04:26 PM
Basgoz NesliDirectorMay 18Sale220.451,889416,4306,030May 22 04:26 PM
GALLAGHER MICHAEL RDirectorMay 04Option Exercise245.2517,6934,339,20820,272May 05 06:34 PM
SAUNDERS BRENT LChairman, President and CEOMar 29Buy242.214310,299131,135Sep 18 08:49 PM
BISARO PAULDirectorMar 02Sale246.6870,00017,267,561235,900Mar 06 06:59 AM
Meury WilliamChief Commercial OfficerDec 08Option Exercise109.1211,8071,288,38048,866Feb 14 09:13 PM
Basgoz NesliDirectorDec 08Sale188.7250094,3605,515Dec 09 05:56 PM
SAUNDERS BRENT LCEO and PresidentNov 21Buy189.135,250992,941106,564Nov 21 04:03 PM
Hilado Maria TeresaChief Financial OfficerNov 11Buy210.641,422299,53613,379Nov 15 05:18 PM